Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Company wins court ruling to continue development of Michigan factory serving EV industry
One Extraordinary Photo: An AP photographer explains how he captured the total eclipse
Members of Team Indonesia attend departure ceremony for Chengdu Universiade
Lang Lang becomes 1st Chinese musician to receive Hollywood Walk of Fame star
Not so Cool Britannia! Noel Gallagher gives damning verdict on Keir Starmer
Chinese books on display at Paris Book Festival 2024
Conservationists give wings to black
Nina Dobrev and boyfriend Shaun White are loved
Strictly star Giovanni Pernice's former partner Rose Ayling
Season of flowers: Bullet trains bound for spring in Xizang
Election 2024: Biden and Trump bypassed the Commission on Presidential Debates
Early settlement of situation on China